Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression

Pharmacology and Therapeutics

Volumn 137, Issue 1, 2013, Pages 1-21

  Pienaar, Ilse S ^a   Chinnery, Patrick F ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Mitochondria; Neuroprotection; Neurorescuing; Oxidative stress; Parkinson's disease; Therapeutics

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; CAFFEINE; CREATININE; ESTROGEN; FLUINDOSTATIN; GW 610742X; GW 855266X; HEAT SHOCK PROTEIN; LEVODOPA; METHYLENE BLUE; MITOQUIDONE; MORTALIN; NICOTINE; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATASE AND TENSIN HOMOLOG INDUCED KINASE 1; PHOSPHOTRANSFERASE; PIOGLITAZONE; RASAGILINE; RIBOFLAVIN; SELEGILINE; SIMVASTATIN; TOCOPHEROL; UBIDECARENONE; UNCLASSIFIED DRUG; URATE;

APOPTOSIS; ARTICLE; AUTOPSY; BIODEGRADATION; CATECHOLAMINE METABOLISM; CELL DIVISION; CELL FUSION; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DYSKINESIA; ESTROGEN THERAPY; EXERCISE; HUMAN; MACROAUTOPHAGY; MITOCHONDRION; MITOPHAGY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; VITAMIN SUPPLEMENTATION;

EID: 84872345893     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.08.010     Document Type: Review

References (339)

1. N. Abbas, C.B. Lucking, S. Ricard, A. Durr, V. Bonifati, and G. De Michele A wide variety of mutations in the parkin gene are responsible for autosomal recessive Parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's disease Hum Mol Genet 8 1999 567 574
2. P.J. Adhihetty, and M.F. Beal Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases Neuromolecular Med 10 2008 275 290
3. L.M. Aguiar, H.V. Nobre Jr., D.S. Macêdo, A.A. Oliveira, R.M. Freitas, and S.M. Vasconcelos Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats Pharmacol Biochem Behav 84 2006 415 419
4. M. Alam, and W.J. Schmidt Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats Behav Brain Res 136 2002 317 324
5. M. Al-Jarrah, K. Pothakos, L. Novikova, I.V. Smirnova, M.J. Kurz, and L. Stehno-Bittel Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of Parkinsonism with severe neurodegeneration Neuroscience 149 2007 28 37
6. H. Alonso-Navarro, F.J. Jiménez-Jiménez, B. Pilo de la Fuente, and J.F. Plaza-Nieto Mecanismos patogénicos de la enfermedad de Parkinson F.J. Jiménez-Jiménez, M.R. Luquin, J.A. Molina, G. Linazasoro, 2nd edition 2008 Viguera Editores S.L. Barcelona 978-84-85424-76-4 425 485
7. B.N. Ames, R. Cathcart, E. Schwiers, and P. Hochstein Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis Proc Natl Acad Sci U S A 78 1981 858 6862
8. P. Andlin-Sobocki, B. Jönsson, H.U. Wittchen, and J. Olesen Cost of disorders of the brain in Europe Eur J Neurol 12 2005 1 27
9. T. Annanmaki, A. Muuronen, and K. Murros Low plasma uric acid level in Parkinson's disease Mov Disord 22 2007 1133 1137
10. A. Ascherio, P.A. LeWitt, K. Xu, S. Eberly, A. Watts, and W.R. Matson Urate as a predictor of the rate of clinical decline in Parkinson disease Arch Neurol 66 2009 1460 1468
11. A. Ascherio, S.M. Zhang, M.A. Hernán, I. Kawachi, G.A. Colditz, and F.E. Speizer Prospective study of caffeine consumption and risk of Parkinson's disease in men and women Ann Neurol 50 2001 56 63
12. H. Atamna, A. Nguyen, C. Schultz, K. Boyle, J. Newberry, and H. Kato Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathway FASEB J 22 2008 703 712
13. J. Baatile, W.E. Langbein, C. Schultz, K. Boyle, J. Newberry, and H. Kato Effect of exercise on perceived quality of life of individuals with Parkinson's disease J Rehabil Res Dev 37 2000 529 534
14. B. Barbiroli, C. Frassineti, P. Martinelli, R. Iotti, R. Lodi, and P. Cortelli Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy Cell Mol Biol (Noisy-le-Grand) 43 1997 741 749
15. P. Bar-On, L. Crews, A.O. Koob, H. Mizuno, A. Adame, and B. Spencer Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease J Neurochem 105 2008 1656 1667
16. S.A. Barrientos, N.W. Martinez, S. Yoo, J.S. Jara, S. Zamorano, and C. Hetz Axonal degeneration is mediated by the mitochondrial transition pore J Neurosci 31 2011 966 978
17. M.F. Beal Therapeutic effects of coenzyme Q10 in neurodegenerative diseases Methods Enzymol 382 2004 473 487
18. M.F. Beal Mitochondria take center stage in aging and neurodegeneration Ann Neurol 58 2005 495 505
19. M.F. Beal, R.T. Matthews, A. Tieleman, and C.W. Shults Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice Brain Res 783 1998 109 114
20. C. Becker, S.S. Jick, and C.R. Meier Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK Drug Saf 31 2008 399 407
21. Y. Ben-Shlomo The epidemiology of Parkinson's disease N.P. Quinn, Parkinsonism 1997 Bailliere-Tindall London 55 68
22. E. Bertrand, W. Lechowicz, G.M. Szpak, and J. Dymecki Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease Folia Neuropathol 35 1997 80 86
23. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat Neurosci 3 2000 1301 1306
24. J. Betts, R.N. Lightowlers, and D.M. Turnbull Neuropathological aspects of mitochondrial DNA disease Neurochem Res 29 2004 505 511
25. E. Bezard, C.E. Gross, M.C. Fournier, S. Dovero, B. Bloch, and M. Jaber Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter Exp Neurol 155 1999 268 273
26. O. Blin, C. Desnuelle, O. Rascol, M. Borg, H. Peyro Saint Paul, and J.P. Azulay Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy Neurol Sci 125 1994 95 101
27. V. Bonifati, P. Rizzu, M.J. van Baren, O. Schaap, G.J. Breedveld, and E. Krieger Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism Science 299 2003 256 259
28. F. Boumezbeur, G.F. Mason, R.A. de Graaf, K.L. Behar, G.W. Cline, and G.I. Shulman Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy J Cereb Blood Flow Metab 30 2010 211 221
29. H. Braak, K.D. Del Tredici, U. Rub, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2003 197 211
30. L.F. Burbulla, C. Schelling, H. Kato, D. Rapaport, D. Woitalia, and C. Schiesling Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis Hum Mol Genet 19 2010 4437 4452
31. T.S. Bürklen, U. Schattner, R. Homayouni, K. Gough, M. Rak, and A. Szeghalmi The creatine kinase/creatine connection to Alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine deposits J Biomed Biotechnol 2006 2006 35936
32. R.S. Burns, C.C. Chiueh, S.P. Markey, M.H. Ebert, D.M. Jacobowitz, and I.J. Kopin A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Proc Natl Acad Sci U S A 80 1983 4546 4550
33. M.J. Calkins, and P.H. Reddy Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons Biochim Biophys Acta 1812 2011 507 513
34. G. Cannino, C.M. Di Liegro, and A.M. Rinaldi Nuclear-mitochondrial interaction Mitochondrion 7 2007 359 366
35. L.A. Carr, and P.P. Rowell Attenuation of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity by tobacco smoke Neuropharmacology 29 1990 311 314
36. C.S. Chan, K.E. Glajch, T.S. Gertler, J.N. Guzman, J.N. Mercer, and A.S. Lewis HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease Nat Neurosci 14 2011 85 92
37. K. Chandran, D. Zhang, J. Joseph, A. Kanthasamy, E.E. Antholine, and A. Kanthasamy Neuroprotective effects of mitochondria-targeted antioxidants against MPTP-induced oxidative damage in mitochondrial aconitase in a preclinical animal model of Parkinson's disease [abstract no. 453.8/CC2] Neuroscience 2008, the Society for Neuroscience's 38th Annual Meeting 2008 Washington, DC, USA
38. D.T. Chang, and I.J. Reynolds Mitochondrial trafficking and morphology in healthy and injured neurons Prog Neurobiol 80 2006 241 268
39. V. Chan-Palay, and E. Asan Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer's type and in Parkinson's disease with and without dementia and depression J Comp Neurol 287 1989 373 392
40. K.R. Chaudhuri, and P. Odin The challenge of non-motor symptoms in Parkinson's disease Prog Brain Res 184 2010 325 341
41. J.F. Chen, K. Xu, J.P. Petzer, R. Staal, Y.H. Xu, and M. Beilstein Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease J Neurosci 21 2001 RC143
42. H.K. Choi, S. Liu, and G. Curhan Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey Arthritis Rheum 52 2005 283 289
43. C.K. Chow Vitamin E and oxidative stress Free Radic Biol Med 11 1991 215 232
44. C.T. Chu Diversity in the regulation of autophagy and mitophagy: lessons from Parkinson's disease Parkinsons Dis 2011 2011 789431
45. Y. Chu, H. Dodiya, P. Aebischer, C.W. Olanow, and J.H. Kordower Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions Neurobiol Dis 35 2009 385 398
46. W.H. Church, and V.L. Ward Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation Brain Res Bull 3 1994 419 425
47. I.E. Clark, M.W. Dodson, C. Jiang, J.H. Cao, J.R. Huh, and J.H. Seol Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin Nature 441 2006 1162 1166
48. C.G. Coimbra, and V.B. Junqueira High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients Braz J Med Biol Res 36 2003 1409 1417
49. C.L. Comella, G.T. Stebbins, N. Brown-Toms, and C.G. Goetz Physical therapy and Parkinson's disease: a controlled clinical trial Neurology 44 1994 376 378
50. K.E. Conley, S.A. Jubrias, C.E. Amara, and D.J. Marcinek Mitochondrial dysfunction: impact on exercise performance and cellular aging Exerc Sport Sci Rev 35 2007 43 49
51. Correira, S. C., Santos, R. X., Cardoso, S., Carvalho, C., Candeias, E., Duarte, A. I., et al. (in press). Alzheimer disease as a vascular disease: where do mitochondria fit? Exp Gerantol (PMID 22824543).
52. G. Costa, J.A. Abin-Carriquiry, and F. Dajas Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra Brain Res 888 2001 336 342
53. A.M. Cuervo, L. Stafanis, R. Fredenburg, P.T. Lansbury, and D. Sulzer Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy Science 305 2004 1292 1295
54. M. Cui, R. Aras, W.V. Christian, P.M. Rappold, M. Hatwar, and J. Panza The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway Proc Natl Acad Sci U S A 106 2009 8043 8048
55. S. Dadakhujaev, H.S. Noh, E.J. Jung, J.Y. Cha, S.M. Baek, and J.H. Ha Autophagy protects the rotenone-induced cell death in α-synuclein overexpressing SH-SY5Y cells Neurosci Lett 472 2010 47 52
56. R.K. Dagda, S.J. Cherra, S.M. Kulich, A. Tandon, D. Park, and C.T. Chu Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission J Biol Chem 284 2009 13843 13855
57. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909
58. K.J. Davies, A. Sevanian, S.F. Muakkassah-Kelly, and P. Hochstein Uric acid-iron ion complexes Biochem J 235 1986 747 754
59. L.M. de Lau, P.J. Koudstaal, A. Hofman, and M.M. Breteler Serum uric acid levels and the risk of Parkinson disease Ann Neurol 58 2005 797 800
60. L.M. de Lau, P.J. Koudstaal, A. Hofman, and M.M. Breteler Serum cholesterol levels and the risk of Parkinson's disease Am J Epidemiol 164 2006 998 1002
61. C. De Nuccio, A. Bernardo, R. De Simone, E. Mancuso, V. Magnaghi, and S. Visentin Peroxisome proliferator-activated receptor γ agonists accelerate oligodendrocyte maturation and influence mitochondrial functions and oscillatory Ca(2+) waves J Neuropathol Exp Neurol 70 2011 900 912
62. G. De Pinieux, P. Chariot, M. Ammi-Saïd, F. Louarn, J.L. Lejonc, and A. Astier Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio Br J Clin Pharmacol 42 1996 333 337
63. M.C. De Rijk, L.J. Launer, K. Berger, M.M. Breteler, J.F. Dartigues, and M. Baldereschi Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurological diseases in the elderly research group Neurology 54 2000 S21 S23
64. L. de Yñigo-Mojado, I. Martin-Ruiz, and J.D. Sutherland Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi PLoS One 6 2011 e21352
65. B. Dehay, J. Bové, N. Rodriquez-Muela, C. Perier, and A. Recasens Pathogenic lysosomal depletion in Parkinson's disease J Neurosci 30 2010 12535 12544
66. T. Dehmer, M.T. Heneka, M. Sastre, J. Dichgans, and J.B. Schulz Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation J Neurochem 88 2004 494 501
67. D.T. Dexter, R.J. Ward, F.R. Wells, S.E. Daniel, A.J. Lees, and T.J. Peters Alpha-tocopherol levels in brain are not altered in Parkinson's disease Ann Neurol 32 1992 591 593
68. R.C. Dodel, Y. Du, K.R. Bales, Z.D. Ling, P.M. Carvey, and S.M. Paul Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4- phenylpyridinum-induced toxicity of cultured fetal rat mesencephalic dopamine neurons Neuroscience 86 1998 701 707
69. R.C. Dodel, Y. Du, K.R. Bales, Z. Ling, P.M. Carvey, and S.M. Paul Caspase-3-like proteases and 6-hydroxydopamine induced neuronal cell death Brain Res Mol Brain Res 64 1999 141 148
70. R.C. Dodel, K.M. Eggert, M.S. Singer, T.E. Eichhorn, O. Pogarell, and W.H. Oertel Costs of drug treatment in Parkinson's disease Mov Disord 13 1998 249 254
71. L. Dong, W. Wang, F. Wang, M. Stoner, J.C. Reed, and M. Harigai Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells J Biol Chem 274 1999 32099 32107
72. R.S. Doody, S.I. Gavrilova, M. Sano, R.G. Thomas, P.S. Aisen, and S.O. Bachurin Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study Lancet 372 2008 207 215
73. W. Duan, B. Ladenheim, R.G. Cutler, I.I. Kruman, J.L. Cadet, and M.P. Mattson Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease J Neurochem 80 2002 101 110
74. J.A. Dykens Neurodegenerative Diseases: Mitochondria and Free Radicals in Pathogenesis M.F. Beal, I. Bodis-Wollner, N. Howell, 1997 John Wiley and Sons 29 55
75. O. Eberhardt, R.V. Coelln, S. Kugler, J. Lindenau, S. Rathke-Hartlieb, and E. Gerhardt Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine model of Parkinson's disease J Neurosci 20 2000 9126 9134
76. M. Etminan, S.S. Gill, and A. Samii Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis Lancet Neurol 4 2005 362 365
77. N. Exner, A.K. Lutz, C. Haass, and K.F. Winklhofer Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences EMBO J 31 2012 3038 3062
78. N. Exner, B. Treske, D. Paquet, K. Holmström, C. Schiesling, and S. Gispert Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin J Neurosci 27 2007 12413 12418
79. S. Fahn A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease Ann Neurol 32 1992 128 132
80. B. Ferger, C. Spratt, C.D. Earl, P. Teismann, W.H. Oertel, and K. Kuschinsky Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo Naunyn Schmiedebergs Arch Pharmacol 358 1998 351 359
81. R.J. Ferrante, J.B. Schulz, N.W. Kowall, and M.F. Beal Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra Brain Res 753 1997 157 162
82. J. Finsterer Mitochondriopathies Eur J Neurol 11 2004 163 186
83. J. Finsterer Parkinson's syndrome and Parkinson's disease in mitochondrial disorders Mov Disord 26 2011 784 791
84. B.E. Fisher, G.M. Petzinger, K. Nixon, E. Hogg, S. Bremmer, and C.K. Meshul Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia J Neurosci Res 77 2004 378 390
85. F. Fornai, O.M. Schlüter, P. Lenzi, M. Gesi, R. Ruffoli, and M. Ferruci Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein Proc Natl Acad Sci U S A 102 2005 3413 3418
86. J.S. Fowler, N.D. Volkow, G.J. Wang, N. Pappas, J. Logan, and R. MacGregor Inhibition of monoamine oxidase B in the brains of smokers Nature 379 1996 733 736
87. S.H. Fox, and A.E. Lang Levodopa-related motor complications - phenomenology Mov Disord 23 2008 S509 S514
88. K. Fuenzalida, R. Quintanilla, P. Ramos, D. Piderit, R.A. Fuentealba, and G. Martinez Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis J Biol Chem 282 2007 37006 37015
89. P.N. Gandhi, S.G. Chen, and A.L. Wilson-Delfosse Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease J Neurosci Res 87 2009 1283 1295
90. X. Gao, H. Chen, H.K. Choi, G. Curhan, M.A. Schwarzschild, and A. Ascherio Diet, urate, and Parkinson's disease risk in men Am J Epidemiol 167 2008 831 838
91. D.M. Gash, K. Rutland, N.L. Hudson, P.G. Sullivan, G. Bing, and W.A. Cass Trichloroethylene: parkinsonism and complex I mitochondrial neurotoxicity Ann Neurol 63 2008 184 192
92. W.J. Geldenhuys, A.S. Darvesh, and D.E. Dluzen Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion Neurochem Int 60 2012 806 808
93. J.C. Gillis, P. Benefield, and D. McTavish Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders Drugs Aging 5 1994 133 152
94. 2+ in the regulation of cellular energetics Biochemistry 51 2012 2959 2973
95. A.L. Goldberg, and F.S. Boches Oxidised proteins in erythrocytes are rapidly degraded by the adenosine triphosphate-dependent proteolytic system Science 215 1982 1107 1109
96. T. Goren, L. Adar, N. Sasson, and Y.M. Weiss Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline J Clin Pharmacol 50 2010 1420 1428
97. D.R. Green, and J.C. Reed Mitochondria and apoptosis Science 281 1998 1309 1312
98. P.S. Green, and J.W. Simpkins Neuroprotective effects of estrogens: potential mechanisms of action Int J Dev Neurosci 18 2000 347 358
99. P.S. Green, and J.W. Simpkins Estrogens and estrogen-like non-feminizing compounds. Their role in the prevention and treatment of Alzheimer's disease Ann N Y Acad Sci 924 2000 93 98
100. J.C. Greene, A.J. Whitworth, I. Kuo, L.A. Andrews, M.B. Feany, and L.J. Pallanck Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants Proc Natl Acad Sci U S A 100 2003 4078 4083
101. R.A. Grunewald Ascorbic acid in the brain Brain Res Brain Res Rev 18 1993 123 133
102. H. Harris, and D.C. Rubinsztein Control of autophagy as a therapy for neurodegenerative disease Nat Rev Neurol 8 2011 108 117
103. A. Hartmann, S. Hunot, P.P. Michel, M.P. Muriel, S. Vyas, and B.A. Faucheux Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease Proc Natl Acad Sci U S A 97 2000 2875 2880
104. M. Hashimoto, P. Bar-On, G. Ho, T. Takenouchi, E. Rockenstein, and L. Crews Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease J Biol Chem 279 2004 23622 23629
105. R.E. Heikkila, L. Manzino, F.S. Cabbat, and R.C. Duvoisin Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine by monoamine-oxidase inhibitors Nature 311 1984 467 469
106. B.J. Henriques, R.K. Olsen, P. Bross, and C.M. Gomes Emerging roles for riboflavin in functional rescue of mitochondrial ß-oxidation flavoenzymes Curr Med Chem 17 2010 3842 3854
107. H.U. Hink, N. Santanam, S. Dikalov, L. McCann, A.D. Nguyen, and S. Parthasarathy Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity Arterioscler Thromb Vasc Biol 22 2002 1402 1408
108. J.G. Hoekstra, K.S. Montine, J. Zhang, and T.J. Montine Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease Alzheimers Res Ther 3 2011 21
109. G.U. Höglinger, J. Féger, A. Prigent, P.P. Michel, K. Parain, and P. Champy Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats J Neurochem 84 2003 491 502
110. A.D. Holmes, D.A. Copland, P.A. Silburn, and H.J. Chenery Acute nicotine enhances strategy-based semantic processing in Parkinson's disease Int J Neuropsychopharmacol 14 2011 877 885
111. G. Hu, R. Antikainen, P. Jousilahti, M. Kivipelto, and J. Tuomilehto Total cholesterol and the risk of Parkinson disease Neurology 70 2008 1972 1979
112. X. Huang, R.D. Abbott, H. Petrovitch, R.B. Mailman, and G.W. Ross Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study Mov Disord 23 2008 1013 1018
113. X. Huang, P. Auinger, S. Eberly, D. Oakes, M. Schwarzschild, and A. Ascherio Serum cholesterol and the progression of Parkinson's disease: results from DATATOP PLoS One 6 2011 e22854
114. X. Huang, H. Chen, W.C. Miller, R.B. Mailman, J.L. Woodard, and P.C. Chen Lower LDL cholesterol levels are associated with Parkinson's disease: a case control study Mov Disord 22 2007 377 381
115. F.M. Huennekens Flavin nucleotides and flavoproteins Experientia 12 1956 1 6
116. P. Ibanez, A.M. Bonnet, B. Débarges, E. Lohmann, F. Tison, and P. Pollak Causal relation between alpha synuclein gene duplication and familial Parkinson's disease Lancet 364 2004 1169 1171
117. M. Iida, I. Miyazaki, K. Tanaka, H. Kabuto, E. Iwata-Ichikawa, and N. Ogawa Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist Brain Res 838 1999 51 59
118. J. Jankovic, and W. Poewe Therapies in Parkinson's disease Curr Opin Neurol 25 2012 433 447
119. B. Jarraya, S. Boulet, G.S. Ralph, C. Jan, G. Bonvento, and M. Azzouz Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia Sci Transl Med 1 2009 2 4
120. P. Jenner, and J.W. Langston Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline Mov Disord 26 2011 2316 2323
121. J. Jin, C. Hulette, Y. Wang, T. Zhang, C. Pan, and R. Wadhwa Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease Mol Cell Proteomics 5 2006 1193 1204
122. J. Jin, G.J. Li, J. Davis, D. Zhu, Y. Wang, and C. Pan Identification of novel proteins associated with both alpha-synuclein and DJ-1 Mol Cell Proteomics 6 2007 845 859
123. M.T. Joghataie, M. Roghani, F. Negahdar, and L. Hashemi Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence Parkinsonism Relat Disord 10 2004 465 468
124. D.C. Jones, P.G. Gunasekar, J.L. Borowitz, and G.E. Isom Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells J Neurochem 74 2000 2296 2304
125. A. Kachroo, M.C. Irizarry, and M.A. Schwarzschild Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration Exp Neurol 223 2010 657 661
126. D.E. Kaempf-Rotzoll, M.G. Traber, and H. Arai Vitamin E and transfer proteins Curr Opin Lipidol 14 2003 249 254
127. H. Kalonia, P. Kumar, and A. Kumar Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats Behav Brain Res 216 2011 220 228
128. F. Kamp, N. Exner, A.K. Lutz, N. Wender, J. Hegermann, and B. Brunner Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1 EMBO J 29 2010 3571 3589
129. R. Kawamori, M. Matsuhisa, J. Kinoshita, K. Mochizuki, M. Niwa, and T. Arisaka Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in noninsulin dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group Diabetes Res Clin Pract 41 1998 35 43
130. T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, and S. Minoshima Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 392 1998 605 608
131. C. Klein, and A. Westenberger Genetics of Parkinson's disease Cold Spring Harb Perspect Med 2 2012 a008888
132. N.W. Kowall, P. Hantraye, E. Brouillet, M.F. Beal, A.C. McKee, and R.J. Ferrante MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons Neuroreport 11 2000 211 213
133. D. Krige, M.T. Carroll, J.M. Cooper, C.D. Marsden, and A.H. Schapira Platelet mitochondrial function in Parkinson's disease: the royal kings and queens Parkinson disease research group Ann Neurol 32 1992 782 788
134. I. Lamensdorf, M.B. Youdim, and J.P. Finberg Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo J Neurochem 67 1996 1532 1539
135. J. Lan, and D.H. Jiang Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice J Neural Transm 104 1997 469 481
136. A.E. Lang, and A.M. Lozano Parkinson's disease. First of two parts N Engl J Med 339 1998 1044 1053
137. J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin Chronic parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
138. Y.-S. Lau, G. Patki, K. Das-Panja, W.D. Le, and S.O. Ahmad Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration Eur J Neurosci 33 2011 1264 1274
139. S. Lee, S.Y. Jeong, W.C. Lim, S. Kim, Y.Y. Park, and X. Sun Mitochondrial fission and fusion mediators, hFis1 and OPA1, modulate cellular senescence J Biol Chem 282 2007 22977 22983
140. J.Y. Lee, Y. Nagano, J.P. Taylor, K.L. Lim, and T.P. Yao Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy J Cell Biol 189 2010 671 679
141. J.J. Lemasters, T. Qian, C.A. Bradham, D.A. Brenner, W.E. Cascio, and L.C. Trost Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death J Bioenerg Biomembr 31 1999 305 319
142. H.M. Li, T. Niki, T. Taira, S.M. Iguchi-Ariga, and H. Ariga Association of DJ-1 with chaperones and enhanced association and colocalization with mitochondrial Hsp70 by oxidative stress Free Radic Res 39 2005 1091 1099
143. M.T. Lin, and M.F. Beal Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases Nature 443 2006 787 795
144. J. Lotharius, L.L. Dugan, and K.L. O'Malley Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons J Neurosci 19 1999 1284 1293
145. C. Lu, and J.S. Armstrong Role of calcium and cyclophilin D in the regulation of mitochondrial permeabilization induced by glutathione depletion Biochem Biophys Res Commun 363 2007 572 577
146. C.B. Lücking, A. Durr, V. Bonifati, J. Vaughan, G. De Michele, and T. Gasser Association between early-onset Parkinson's disease and mutations in the parkin gene N Engl J Med 342 2000 1560 1567
147. M. Mabandla, L. Kellaway, A. St Clair Gibson, and V.A. Russell Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle Metab Brain Dis 19 2004 43 50
148. C. Mancuso, G. Scapagini, D. Currò, A.M. Giuffrida Stella, C. De Marco, and D.A. Butterfield Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders Front Biosci 12 2007 1107 1123
149. W. Mandemakers, V.A. Morais, and B. De Strooper A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases J Cell Sci 120 2007 1707 1716
150. V.M. Mann, J.M. Cooper, D. Krige, S.E. Daniel, A.H. Schapira, and C.D. Marsden Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease Brain 115 1992 333 342
151. I. Martin, V.L. Dawson, and T.M. Dawson Recent advances in the genetics of Parkinson's disease Annu Rev Genomics Hum Genet 12 2011 301 325
152. M. Martinez-Vicente, Z. Talloczy, S. Kaushik, A.C. Massey, J. Mazzulli, and E.V. Mosharov Dopamine-modified α-synuclein blocks chaperone mediated autophagy J Clin Invest 118 2008 777 778
153. W. Maruyama, Y. Akao, M.B. Youdim, and M. Naoi Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022 J Neural Transm Suppl 2000 2000 171 186
154. W. Maruyama, M.B. Youdim, and M. Naoi Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022 Ann N Y Acad Sci 939 2001 320 329
155. N. Matsuda, S. Sato, K. Shiba, K. Okatsu, K. Saisho, and C.A. Gautier PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy J Cell Biol 189 2010 211 221
156. R.T. Matthews, R.J. Ferrante, P. Klivenyi, L. Yang, A.M. Klein, and G. Mueller Creatine and cyclocreatine attenuate MPTP neurotoxicity Exp Neurol 157 1999 142 149
157. M.K. McCoy, and M.R. Cookson DJ-1 regulation of mitochondrial function and autophagy through oxidative stress Autophagy 7 2011 531 532
158. G.E. Meredith, S. Totterdell, J.A. Potashkin, and D.J. Surmeier Modeling PD pathogenesis in mice: advantages of a chronic PMTP protocol Parkinsonism Relat Disord 14 2008 S112 S115
159. A.H. Merrill Jr., J.D. Lambeth, D.E. Edmondson, and D.B. McCormick Formation and mode of action of flavoproteins Annu Rev Nutr 1 1981 281 317
160. C.K. Meshul, D. Kamel, C. Moore, T.S. Kay, and L. Krentz Nicotine alters striatal glutamate function and decreases the apomorphine induced contralateral rotations in 6-OHDA-lesioned rats Exp Neurol 175 2002 257 274
161. M. Misiak, C. Beyer, and S. Arnold Gender-specific role of mitochondria in the vulnerability of 6-hydroxydopamine-treated mesencephalic neurons Biochim Biophys Acta 1797 2010 1178 1188
162. I. Miyai, Y. Fujimoto, Y. Ueda, H. Yamamoto, S. Nozaki, and T. Saito Treadmill training with body weight support: its effect on Parkinson's disease Arch Phys Med Rehabil 81 2000 849 852
163. Y. Miyake, K. Tanaka, W. Fukushima, S. Sasaki, C. Kiyohara, and Y. Tsuboi Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan J Neurol Sci 293 2010 82 86
164. Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, and K. Cusi Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J Clin Endocrinol Metab 87 2002 2784 2791
165. Y. Mizuno, S. Matuda, H. Yoshino, H. Mori, N. Hattori, and S. Ikebe An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease Ann Neurol 35 1994 204 210
166. H. Mochizuki, H. Hayakawa, M. Migita, M. Shibata, R. Tanaka, and A. Suzuki An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease Proc Natl Acad Sci U S A 98 2001 10918 10923
167. V.A. Morais, P. Verstreken, A. Roethig, J. Smet, A. Snellinx, and M. Vanbrabant Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function EMBO Mol Med 1 2009 99 111
168. A. Mordente, G.E. Martorana, G. Minotti, and B. Giardina Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone) Chem Res Toxicol 11 1998 54 63
169. S.A. Mortensen, A. Leth, E. Agner, and M. Rohde Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors Mol Aspects Med 18 1997 S137 S144
170. H. Mortiboys, K.K. Johansen, J.O. Aasly, and O. Bandmann Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2 Neurology 75 2010 2017 2020
171. K. Murakami, Y. Miyake, S. Sasaki, K. Tanaka, W. Fukushima, and C. Kiyohara Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: a case-control study in Japan Br J Nutr 104 2010 757 764
172. M.P. Murphy, and R.A. Smith Targeting antioxidants to mitochondria by conjugation to lipophilic cations Annu Rev Pharmacol Toxicol 47 2007 629 656
173. K. Nakaso, S. Ito, and K. Nakashima Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells Neurosci Lett 432 2008 146 150
174. D.P. Narendra, S.M. Jin, A. Tanaka, D.F. Suen, C.A. Gautier, and J. Shen PINK1 is selectively stabilized on impaired mitochondria to activate Parkin PLoS Biol 8 2010 e1000298
175. D. Narendra, A. Tanaka, D.F. Suen, and R.J. Youle Parkin is recruited selectively to impaired mitochondria and promotes their autophagy J Cell Biol 183 2008 795 803
176. A. Navarro, and A. Boveris Brain mitochondrial dysfunction in aging: conditions that improve survival, neurological performance and mitochondrial function Front Biosci 12 2007 1154 1163
177. M. Neumann, V. Muller, K. Gorner, H.A. Kretzschmar, C. Haass, and P.J. Kahle Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease Acta Neuropathol 107 2004 489 496
178. W. Neupert, and J.M. Herrmann Translocation of proteins into mitochondria Annu Rev Biochem 76 2007 723 749
179. M. Niso-Santano, J.M. Bravo-San Pedro, R. Gómez-Sánchez, V. Climent, G. Soler, and J.M. Fuentes ASK1 overexpression accelerates paraquat-induced autophagy via endoplasmic reticulum stress Toxicol Sci 119 2011 156 168
180. A.M. O'Carroll, C.J. Fowler, J.P. Phillips, I. Tobbia, and K.F. Tipton The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions Naunyn Schmiedebergs Arch Pharmacol 322 1983 198 202
181. R. O'Lone, K. Knorr, I.Z. Jaffe, M.E. Schaffer, P.G. Martini, and R.H. Karas Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species Mol Endocrinol 21 2007 1281 1296
182. I.N. Odunze, L.K. Klaidma, and J.D. Adams Jr. MPTP toxicity in the mouse brain and vitamin E Neurosci Lett 108 1990 346 349
183. D. Offen, I. Ziv, E. Melamed, and A. Hochman Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease Exp Neurol 141 1996 32 39
184. C.W. Olanow, R. Hauser, J. Jankovic, W. Langston, A. Lang, and W. Poewe A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics Mov Disord 23 2008 2194 2201
185. J.M. Palacios, and K.H. Wiederhold Acute administration of 1-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP), a compound producing Parkinsonism in humans, stimulates, [2-14C]deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains Brain Res 301 1984 187 191
186. E. Palombo, L.J. Porrino, K.S. Bankiewicz, A.M. Crane, I.J. Kopin, and L. Sokoloff Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates Brain Res 453 1988 227 234
187. A. Parihar, M.S. Parihar, W.J. Zenebe, and P. Ghafourifar Statins lower calcium-induced oxidative stress in isolated mitochondria Hum Exp Toxicol 31 2012 355 363
188. W.D. Parker Jr., S.J. Boyson, and J.K. Parks Abnormalities of the electron transport chain in idiopathic Parkinson's disease Ann Neurol 26 1989 719 723
189. W.D. Parker Jr., J.K. Parks, and R.H. Swerdlow Complex I deficiency in Parkinson's disease frontal cortex Brain Res 1189 2008 215 218
190. Parkinson Study Group A controlled trial of rasagiline in early Parkinson's disease: the TEMPO Study Arch Neurol 59 2002 1937 1943
191. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study Arch Neurol 62 2005 241 248
192. Parkinson Study Group POETRY Investigators A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease Parkinsonism Relat Disord 17 2011 757 760
193. T.I. Peng, and J.T. Greenamyre Privileged access to mitochondria of calcium influx through N-methyl-d-aspartate receptors Mol Pharmacol 53 1998 974 980
194. C. Perier, J. Bové, D.C. Wu, B. Dehay, and D.K. Choi Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease Proc Natl Acad Sci U S A 104 2007 8161 8166
195. C. Perier, K. Tieu, C. Guégan, C. Caspersen, V. Jackson-Lewis, and V. Carelli Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage Proc Natl Acad Sci U S A 102 2005 19126 19131
196. C. Perier, and M. Vila Mitochondrial biology and Parkinson's disease Cold Spring Harb Perspect Med 2 2012 a009332
197. J.S. Perlmutter New insights into the pathophysiology of Parkinson's disease: the challenge of positron emission tomography Trends Neurosci 11 1988 203 208
198. E. Perlson, S. Maday, M.M. Fu, A.J. Moughamian, and E.L. Holzbaur Retrograde axonal transport: pathways to cell death? Trends Neurosci 33 2010 335 344
199. T.L. Perry, V.W. Yong, R.M. Clavier, K. Jones, J.M. Wright, and J.G. Foulks Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine by four different antioxidants in the mouse Neurosci Lett 60 1985 109 114
200. T.L. Perry, V.W. Yong, R.M. Clavier, K. Jones, J.M. Wright, and J.G. Foulks Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine J Neurol Sci 81 1987 321 331
201. N. Pfanner, N. Wiedeman, C. Meisinger, and T. Lithgow Assembling the mitochondrial outer membrane Nat Struct Mol Biol 11 2004 1044 1048
202. F. Pickford, E. Masliah, M. Britschgi, K. Lucin, R. Narasimhan, and P.A. Jaeger The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice J Clin Invest 118 2008 2190 2199
203. I.S. Pienaar, D. Burn, C. Morris, and D. Dexter Synaptic protein alterations in Parkinson's disease Mol Neurobiol 45 2012 126 143
204. Pienaar, I. S., Lu, B., & Schallert, T. (in press). Closing the gap between clinic and cage: sensori-motor and behavioral testing regimens in neurotoxin-induced animal models of Parkinson's disease. Neurosci Biobehav Rev (PMID 22910679).
205. I.S. Pienaar, T. Schallert, S. Hattingh, and W.M. Daniels Behavioral and quantitative mitochondrial proteome analyses of the effects of simvastatin: implications for models of neural degeneration J Neural Transm 116 2009 791 806
206. C.J. Pike Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease J Neurochem 72 1999 1552 1563
207. V.N. Pivtoraiko, A.J. Harrington, B.J. Mader, A.M. Luker, G.A. Caldwell, and K.A. Caldwell Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction J Neurochem 114 2010 1193 1204
208. N.P. Poulton, and G.D. Muir Treadmill training ameliorates dopamine loss but not behavioral deficits in hemi-parkinsonian rats Exp Neurol 193 2005 181 197
209. H.J. Powers A study of maternofetal iron transfer in the riboflavin-deficient rat J Nutr 117 1987 852 856
210. H.J. Powers Riboflavin (vitamin B-2) and health Am J Clin Nutr 77 2003 1352 1360
211. H.J. Powers, C.J. Bates, and J.M. Duerden Effects of riboflavin deficiency in rats on some aspects of iron metabolism Int J Vitam Nutr Res 53 1983 371 376
212. A.J. Primeau, P.J. Adhihetty, and D.A. Hood Apoptosis in heart and skeletal muscle Can J Appl Physiol 27 2010 349 395
213. S. Przedborski, V. Jackson-Lewis, and S. Fahn Anti-parkinsonian therapies and brain mitochondrial complex I activity Mov Disord 10 1995 312 317
214. M. Quik, N. Parameswaran, S.E. McCallum, T. Bordia, S. Bao, and A. McCormack Chronic oral nicotine treatment protects against striatal degeneration in MPTP treated primates J Neurochem 98 2006 1866 1875
215. D. Rapaport Finding the right organelle. Targeting signals in mitochondrial outer-membrane proteins EMBO Rep 4 2003 948 952
216. D. Rapaport How does the TOM complex mediate insertion of precursor proteins into the mitochondrial outer membrane? J Cell Biol 171 2005 419 423
217. O. Rascol, D.J. Brooks, E. Melamed, W. Oertel, W. Poewe, and F. Stocchi Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double- blind, parallel-group trial Lancet 365 2005 947 954
218. O. Rascol, C.J. Fitzer-Attas, R. Hauser, J. Jankovic, A. Lang, and J.W. Langston A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes Lancet Neurol 10 2011 415 423
219. M. Reale, M. Pesce, M. Priyadarshini, M.A. Kamal, and A. Patruno Mitochondria as an easy target to oxidative stress events in Parkinson's disease CNS Neurol Disord Drug Targets 11 2012 430 438
220. P.H. Reddy Mitochondrial medicine for aging and neurodegenerative diseases Neuromolecular Med 10 2008 291 315
221. P.H. Reddy, R. Tripathi, Q. Troung, K. Tirumala, T.P. Reddy, and V. Anekonda Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer disease: implications to mitochondria-targeted antioxidant therapeutics Biochim Biophys Acta 1822 2011 639 649
222. Y.R. Ren, Y. Nishida, K. Yoshimi, T. Yasuda, K. Jishage, and T. Uchihara Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain J Neurochem 98 2006 1810 1816
223. I. Reuter, M. Engelhardt, K. Stecker, and H. Baas Therapeutic value of exercise training in Parkinson's disease Med Sci Sports Exerc 31 1999 1544 1549
224. P. Rizzu, D.A. Hinkle, V. Zhukareva, V. Bonifati, L.A. Severijnen, and D. Martinez DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia Ann Neurol 55 2004 113 118
225. R.L. Rodnitzky Upcoming treatments in Parkinson's disease, including gene therapy Parkinsonism Relat Disord 18 2012 S37 S40
226. S. Rodriguez-Cuenca, H.M. Cochemé, A. Logan, I. Abakumova, T.A. Prime, and C. Rose Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice Free Radic Biol Med 48 2009 161 172
227. M. Roghani, and G. Behzadi Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: Behavioral and histochemical evidence Brain Res 892 2001 211 217
228. J.M. Rose, S.S. Novoselov, P.A. Robinson, and M.E. Cheetham Molecular chaperone-mediated rescue of mitophagy by a Parkin RING1 domain mutant Hum Mol Genet 20 2011 16 27
229. F.L. Rosenfeldt, S. Pepe, A. Linnane, P. Nagley, M. Rowland, and R. Ou Coenzyme Q10 protects the aging heart against stress: studies in rats, human tissues, and patients Ann N Y Acad Sci 959 2002 355 359
230. G.W. Ross, R.D. Abbott, H. Petrovitch, D.M. Morens, A. Grandinetti, and K.H. Tung Association of coffee and caffeine intake with the risk of Parkinson disease JAMA 283 2000 2674 2679
231. T. Rundek, A. Naini, R. Sacco, K. Coates, and S. DiMauro Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke Arch Neurol 61 2004 889 892
232. K. Saaksjarvi, P. Knekt, H. Rissanen, M.A. Laaksonen, A. Reunanen, and S. Männistö Prospective study of coffee consumption and risk of Parkinson's disease Eur J Clin Nutr 62 2008 908 915
233. M. Sadeghian, L. Marinova-Mutafchieva, L. Broom, J.B. Davis, D. Virley, and A.D. Medhurst Full and partial peroxisome proliferation-activated receptorâ€γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression J Neuroimmunol 246 2010 69 77
234. A. Samii, B.C. Carleton, and M. Etminan Statin use and the risk of Parkinson disease: a nested case control study J Clin Neurosci 15 2008 1272 1273
235. J. Saura, N. Andres, C. Andrade, J. Ojuel, K. Eriksson, and N. Mahy Biphasic and region-specific MAO-B response to aging in normal human brain Neurobiol Aging 18 1997 497 507
236. N. Scarmeas, Y. Stern, R. Mayeux, J.J. Manly, N. Schupf, and J.A. Luchsinger Mediterranean diet and mild cognitive impairment Arch Neurol 66 2009 216 225
237. A.H. Schapira The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease Mov Disord 2008 S515 S520
238. A.H. Schapira Mitochondria in the aetiology and pathogenesis of Parkinson's disease Lancet Neurol 7 2008 97 109
239. A.H. Schapira Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects CNS Drugs 25 2011 1061 1071
240. A.H. Schapira, J.M. Cooper, D. Dexter, P. Jenner, J.B. Clark, and C.D. Marsden Mitochondrial complex I deficiency in Parkinson's disease Lancet 1 1989 1269
241. W.L. Scheider, L.A. Hershey, J.E. Vena, T. Holmlund, J.R. Marshall, and Freudenheim Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease Mov Disord 12 1997 190 196
242. E.A. Schon, and S. Przedborski Mitochondria: the next (neurode)generation Neuron 70 2011 1033 1053
243. K. Schoonjans, B. Staels, and J. Auwerx The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation Biochim Biophys Acta 1302 1996 93 109
244. M.A. Schwarzschild, S.R. Schwid, K. Marek, A. Watts, A.E. Lang, and D. Oakes Serum urate as a predictor of clinical and radiographic progression in Parkinson disease Arch Neurol 65 2008 716 723
245. G. Scigliano, M. Musicco, P. Soliveri, I. Piccolo, G. Ronchetti, and F. Girotti Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study Stroke 37 2006 1184 1188
246. G. Scigliano, G. Ronchetti, and F. Girotti Plasma cholesterol and Parkinson's disease: is the puzzle only apparent? Mov Disord 25 2010 659 660
247. L. Shan, K. Bossers, S. Luchetti, R. Balesar, N. Lethbridge, and P.L. Chazot Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a post-mortem study Neurobiol Aging 33 2012 1488.e10 1488.e13
248. T.B. Sherer, J.R. Richardson, C.M. Testa, B.B. Seo, A.V. Panov, and T. Yagi Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease J Neurochem 100 2007 1469 1479
249. T.B. Sherer, P.A. Trimmer, K. Borland, J.K. Parks, J.P. Bennett Jr., and J.B. Tuttle Chronic reduction in complex I function alters calcium signalling in SH-SY5Y neuroblastoma cells Brain Res 891 2001 94 105
250. K.C. Simon, H. Chen, X. Gao, M.A. Schwarzschild, and A. Ascherio Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease Mov Disord 24 2009 1359 1365
251. J.W. Simpkins, S.H. Yang, S.N. Sarkar, and V. Pearce Estrogen actions on mitochondria - physiological and pathological implications Mol Cell Endocrinol 290 2008 51 59
252. T. Simuni, E. Borushko, M.J. Avram, S. Miskevics, A. Martel, and C. Zadikoff Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study Mov Disord 25 2010 2863 2866
253. M. Singh, G. Setalo Jr., X. Guan, M. Warren, and C.D. Toran-Allerand Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways J Neurosci 19 1999 1179 1188
254. K. Singh, S. Singh, N.K. Singhal, A. Sharma, D. Parmar, and M.P. Singh Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: implications in neuroprotection mechanism Chem Biol Interact 185 2010 81 93
255. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, and J. Kachergus Alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003 841
256. S. Sirivech, J. Driskell, and E. Frieden NADH-FMNoxidoreductase activity and iron content of organs from riboflavin and iron-deficient rats J Nutr 107 1977 739 745
257. R.A. Smith, and M.P. Murphy Animal and human studies with the mitochondria-targeted antioxidant MitoQ Ann N Y Acad Sci 1201 2010 96 103
258. R.A.J. Smith, C.M. Porteous, A.M. Gane, and M.P. Murphy Delivery of bioactive molecules to mitochondria in vivo Proc Natl Acad Sci U S A 100 2003 5407 5412
259. B.J. Snow, F.L. Rolfe, M.M. Lockhart, C.M. Frampton, J.D. O'Sullivan, and V. Fung A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease Mov Disord 25 2010 1670 1674
260. Solesio, M. E., Prime, T. A., Logan, A., Murphy, M. P., Del Mar Arroyo-Jimenez, M., Jordán, J., et al. (in press). The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease. Biochim Biophys Acta (PMID 22846607).
261. B. Spencer, R. Potkar, M. Trejo, E. Rockenstein, C. Patrick, and R. Gindi Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases J Neurosci 29 2009 13578 13588
262. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
263. A.A. Starkov, B.M. Polster, and G. Fiskum Regulation of hydrogen peroxide production by brain mitochondria by calcium and Bax J Neurochem 83 2002 220 228
264. K. Stepień, M. Tomaszewski, and S.J. Czuczwar Neuroprotective properties of statins Pharmacol Rep 57 2005 561 569
265. F.H. Sterky, A.F. Hoffman, D. Milenkovic, B. Bao, A. Paganelli, and D. Edgar Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons Hum Mol Genet 21 2012 1078 1089
266. A. Storch, W.H. Jost, P. Vieregge, J. Spiegel, W. Greulich, and J. Durner Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease Arch Neurol 64 2007 938 944
267. J.C. Strum, R. Shehee, D. Virley, J. Richardson, M. Mattie, and P. Selley Rosiglitazone induces mitochondrial biogenesis in mouse brain J Alzheimers Dis 11 2007 45 51
268. M. Suno, and A. Nagaoka Inhibition of brain mitochondrial swelling by idebenone Arch Gerontol Geriatr 8 1989 299 305
269. C.R. Swanson, V. Joers, V. Bondarenko, K. Brunner, H.A. Simmons, and T.E. Ziegler The PPAR- γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys J Neuroinflammation 8 2011 91
270. H.H. Szeto Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury Antioxid Redox Signal 10 2007 601 619
271. K.K. Tai, L. Pham, and D.D. Truong Idebedone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY5Y cells Neurotox Res 20 2011 321 328
272. C.M. Tanner, F. Kamel, G.W. Ross, J.A. Hoppin, S.M. Goldman, and M. Korell Rotenone, paraquat and Parkinson's disease Environ Health Perspect 119 2011 866 872
273. C.M. Tanner, and J.W. Langston Do environmental toxins cause Parkinson's disease? A critical review Neurology 40 1990 1 30
274. D. Tarsy Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease JAMA 307 2012 2305 2314
275. D.J. Taylor, D. Krige, P.R. Barnes, G.J. Kemp, M.T. Carroll, and V.M. Mann A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease J Neurol Sci 125 1994 77 81
276. C.M. Testa, T.B. Sherer, and J.T. Greenamyre Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures Mol Brain Res 13 2005 109 118
277. The NINDS NET-PD Investigators A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results Clin Neuropharmacol 31 2008 141 150
278. K. Tiemann, and J.J. Rossi RNAi-based therapeutics - current status, challenges and prospects EMBO Mol Med 1 2009 142 151
279. K. Tieu, H. Ischiropoulos, and S. Przedborski Nitric oxide and reactive oxygen species in Parkinson's disease IUBMB Life 55 2003 329 335
280. J.L. Tillerson, W.M. Caudle, M.E. Reverón, and G.W. Miller Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease Neuroscience 119 2003 899 911
281. H. Tohgi, T. Abe, S. Takahashi, and T. Kikuchi The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease J Neural Transm Park Dis Dement Sect 6 1993 119 126
282. Y. Tokumitsu, and M. Ui The incorporation of 32 P i into intramitochondrial ADP fraction dependent on the substrate-level phosphorylation Biochim Biophys Acta 292 1973 310 324
283. E.M. Valente, P.M. Abou-Sleiman, V. Caputo, M.M. Muqit, K. Harvey, and S. Gispert Hereditary early-onset Parkinson's disease caused by mutations in PINK1 Science 304 2004 1158 1160
284. J. Vamecq, and N. Latruffe Medical significance of peroxisome proliferator-activated receptors Lancet 354 1999 141 148
285. J. Van Horssen, M.E. Witte, G. Schreibelt, and H.E. de Vries Radical changes in multiple sclerosis pathogenesis Biochim Biophys Acta 1812 2011 141 150
286. V.S. Van Laar, B. Arnold, S.J. Cassady, C.T. Chu, E.A. Burton, and S.B. Berman Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization Hum Mol Genet 20 2011 927 940
287. M. Vila, V. Jackson-Lewis, S. Vukosavic, R. Djaldetti, G. Liberatore, and D. Offen Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease Proc Natl Acad Sci U S A 98 2001 2837 2842
288. G. Villafane, P. Cesaro, A. Rialland, S. Baloul, S. Azimi, and C. Bourdet Chronic high dose transdermal nicotine in Parkinson's disease: an open trial Eur J Neurol 14 2007 1313 1316
289. 2+ handling in human complex I deficiency J Biol Chem 279 2004 40328 40336
290. C. Vives-Bauza, C. Zhou, Y. Huang, M. Cui, R.L. de Vries, and J. Kim PINK1-dependent recruitment of Parkin to mitochondria in mitophagy Proc Natl Acad Sci U S A 107 2010 378 383
291. F. Von Lewinski, and B.U. Keller Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS Trends Neurosci 28 2005 494 500
292. X. Wang, T.G. Petrie, Y. Liu, J. Liu, H. Fujioka, and X. Zhu Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction J Neurochem 121 2012 830 839
293. G.J. Wang, N.D. Volkow, J.S. Fowler, D. Franceschi, J. Logan, and N.R. Pappas PET studies of the effects of aerobic exercise on human striatal dopamine release J Nucl Med 41 2000 1352 1356
294. T.J. Webster, D.J. Naylor, D.J. Hartman, P.B. Høj, and N.J. Hoogenraad cDNA cloning and efficient mitochondrial import of pre-mtHSP70 from rat liver DNA Cell Biol 13 1994 1213 1220
295. Y. Wen, W. Li, E.C. Poteet, L. Xie, C. Tan, and L.J. Yan Alternative mitochondrial electron transfer as a novel strategy for neuroprotection J Biol Chem 286 2011 16504 16515
296. B. Wolozin, S.W. Wang, N.C. Li, A. Lee, T.A. Lee, and L.E. Kazis Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease BMC Med 5 2007 20
297. E.C. Wolters Psychiatric complications in the treatment of Parkinson's disease Adv Neurol 86 2001 385 393
298. J. Wu, Q. Li, and I. Bezprozvanny Evaluation of Dimebon in cellular model of Huntington's disease Mol Neurodegener 3 2008 15
299. M. Xilouri, and L. Stefanis Autophagic pathways in Parkinson disease and related disorders Expert Rev Mol Med 13 2011 e8
300. L. Xu, L.A. Voloboueva, Y. Ouyang, J.F. Emery, and R.G. Giffard Overexpression of mitochondrial Hsp70/Hsp75 in rat brain protects mitochondria, reduces oxidative stress, and protects from focal ischemia J Cereb Blood Flow Metab 29 2009 365 374
301. F. Yamakura, H. Taka, T. Fujimura, and K. Murayama Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine J Biol Chem 273 1998 14085 14089
302. L. Yang, N.Y. Calingasan, E.J. Wille, K. Cormier, K. Smith, and R.J. Ferrante Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases J Neurochem 109 2009 1427 1439
303. Y. Yang, Y. Ouyang, L. Yang, M.F. Beal, A. McQuibban, and H. Vogel Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery PNAS 105 2008 7070 7075
304. L. Yang, K. Zhao, N.Y. Calingasan, G. Luo, H.H. Szeto, and M.F. Beal Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity Antioxid Redox Signal 11 2009 2095 2104
305. H. Yang, X. Zhou, X. Liu, L. Yang, Q. Chen, and D. Zhao Mitochondrial dysfunction induced by knockdown of mortalin is rescued by Parkin Biochem Biophys Res Commun 410 2011 114 120
306. T. Yokota, K. Igarashi, T. Uchihara, K. Jishage, H. Tomita, and A. Inaba Delayed-onset ataxia in mice lacking alpha-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress Proc Natl Acad Sci U S A 98 2001 15185 15190
307. M.B. Youdim, A. Gross, and J.P. Finberg Rasagiline N-propargyl-1R(+)- aminoindan, a selective and potent inhibitor of mitochondrial monoamine oxidase B Br J Pharmacol 132 2001 500 506
308. Z.F. Yu, A.J. Bruce-Keller, Y. Goodman, and M.P. Mattson Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo J Neurosci Res 53 1998 613 625
309. S.M. Zhang, M.A. Hernan, H. Chen, D. Spiegelman, W.C. Willett, and A. Ascherio Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk Neurology 59 2002 1161 1169
310. K. Zhao, G.M. Zhao, D. Wu, Y. Soong, A.V. Birk, and P.W. Schiller Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury J Biol Chem 279 2004 34682 34690
311. B. Zheng, Z. Liao, J.J. Locascio, K.A. Lesniak, S.S. Roderick, and M.L. Watt PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease: a pilot dose escalation study Sci Transl Med 2 2010 52 73
312. J.H. Zhu, C. Horbinski, F. Guo, S. Watkins, Y. Uchiyama, and C.T. Chu Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death Am J Pathol 170 2007 75 86
313. R.M. Zweig, W.R. Jankel, J.C. Hedreen, R. Mayeux, and D.L. Price The pedunculopontine nucleus in Parkinson's disease Ann Neurol 26 1989 41 46
314. A.A. Abdin, and H.E. Hamouda Mechanism of the neuroprotective role of coenzyme Q10 with or without l-dopa in rotenone-induced Parkinsonism Neuropharmacology 55 2008 1340 1346
315. Y. Akao, W. Maruyama, S. Shimizu, Y. Nakagawa, M. Shamoto-Nagai, and M.B. Youdim Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan J Neurochem 82 2002 913 923
316. Z.B. Andrews, B. Horvath, C.J. Barnstable, J. Elsworth, L. Yang, and M.F. Beal Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease J Neurosci 25 2005 184 191
317. M.F. Beal, D.R. Henshaw, B.G. Jenkins, B.R. Rosen, and J.B. Schulz Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate Ann Neurol 36 1994 882 888
318. R. Castino, G. Lazzeri, P. Lenzi, N. Bellio, C. Follo, and M. Ferrucci Suppression of autophagy precipitates neuronal cell death following low doses of methamphetamine J Neurochem 106 2008 1426 1439
319. K.C. Choi, S.H. Kim, J.Y. Ha, S.T. Kim, and J.H. Son A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death J Neurochem 112 2010 366 376
320. Q.L. Deveraux, E. Leo, H.R. Stennicke, K. Welsh, G.S. Salvesen, and J.C. Reed Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases EMBO J 18 1999 5242 5251
321. D.A. Di Monte Mitochondrial DNA and Parkinson's disease Neurology 41 1991 38 42
322. D.M. Dykxhoorn, C.D. Novina, and P.A. Sharp Killing the messenger: short RNAs that silence gene expression Nat Rev Mol Cell Biol 4 2003 457 467
323. Effects of coenzyme Q10 (CoQ) in Parkinson disease (QE3) http://clinicaltrials.gov/ct2/show/NCT00740714?term=QE3+Parkinson'sandrank=1 Accessed April 24th, 2012
324. C. Gomez-Santos, I. Ferrer, A.F. Santidrián, M. Barrachina, J. Gil, and S. Ambrosio Dopamine induces autophagic cell death and α-synuclein increase in human neuroblastoma SH-SY5Y cells J Neurosci Res 73 2003 341 350
325. J.N. Guzman, J. Sanchez-Padilla, D. Wokosin, J. Kondapalli, E. Ilijic, and P.T. Schumacker Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 Nature 468 2010 696 700
326. T.L. Horvath, S. Diano, C. Leranth, L.M. Garcia-Segura, M.A. Cowley, and M. Shanabrough Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease Endocrinology 144 2003 2757 2760
327. P. Jenner, A.H. Schapira, and C.D. Marsden New insights into the cause of Parkinson's disease Neurology 42 1992 2241 2250
328. C.S. Lam, V. Korzh, and U. Strahle Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP Eur J Neurosci 21 2005 1758 1762
329. J. Liu, J.D. Farmer Jr., W.S. Lane, J. Friedman, I. Weismann, and S.L. Schreiber Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes Cell 66 1991 807 815
330. C.W. Olanow, O. Rascol, R. Hauser, P.D. Feigin, J. Jankovic, and A. Lang A double-blind, delayed-start trial of Rasagiline in Parkinson's disease N Engl J Med 361 2009 1268 1278
331. A.H.V. Schapira, and C.W. Olanow Neuroprotection in Parkinson disease. Mysteries, myths and misconceptions JAMA 291 2004 358 364
332. C.W. Shults, M.F. Beal, D. Fontaine, K. Nakano, and R.H. Haas Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients Neurology 50 1998 793 795
333. C.W. Shults, R.H. Haas, D. Passov, and M.F. Beal Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and non-parkinsonian subjects Ann Neurol 42 1997 261 264
334. F. Simunovic, M. Yi, Y. Wang, L. Macey, L.T. Brown, and A.M. Krichevsky Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology Brain 132 2009 1795 1809
335. M. Somayajulu, S. McCarthy, M. Hung, M. Sikorska, H. Borowy-Borowski, and S. Pandey Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by coenzyme Q10 Neurobiol Dis 18 2005 618 627
336. R. Stocker, V.W. Bowry, and B. Frei Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol Proc Natl Acad Sci U S A 88 1991 1646 1650
337. J.S. Tauskela MitoX - a mitochondria-targeted antioxidant IDrugs 10 2007 399 412
338. The NINDS NET-PD Investigators A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease Neurology 68 2007 20 28
339. O. Weinreb, T. Amit, O. Bar-Am, O. Chillag-Talmor, and M.B. Youdim Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway Ann N Y Acad Sci 1053 2005 348 355